Clinical Trial Detail

NCT ID NCT04467801
Title Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Kansas Medical Center
Indications

lung non-small cell carcinoma

Therapies

Ipatasertib

Docetaxel + Ipatasertib

Age Groups: adult senior

Additional content available in CKB BOOST